Uceris, Canasa, low dose naltrexone and alpha lipoic acid

[Justine]

Hi,

Could you please let me know the safety of Uceris, Canasa, low dose naltrexone, turmeric, reservatrol, and alpha lipoic acid? I am breastfeeding a 7 month old.
Thank you!

[admin]

Justine:

Uceris is oral budesonide. Its a potent steroid that is NOT absorbed orally, and only works in the GI tract.

Mesalamine (Canasa) levels in milk are low. See article I just published below.

Naltrexone is poorly aborbed orally, only 1.4% of maternal dose.

Turmeric...don't know anything about it in milk.

Resveratrol....commonly found in red wine. No data in breastmilk. use cautiously.

Alpha Lipoic Acid ....No data in breastmilk. use cautiously.


Tom Hale Ph.D.







Send to ([url]https://www.ncbi.nlm.nih.gov/pubmed/?term=mesalamine+hale+tw#[/url])


Breastfeed Med. 2019 Mar;14(2):98-101. doi: 10.1089/bfm.2018.0111. Epub 2018 Nov 15. Determination of Mesalamine levels in Human Milk as a Function of Dose.

Datta P ([url]https://www.ncbi.nlm.nih.gov/pubmed/?term=Datta%20P%5BAuthor%5D&cauthor=true&cauthor_u id=30431332[/url])¹, Rewers-Felkins K ([url]https://www.ncbi.nlm.nih.gov/pubmed/?term=Rewers-Felkins%20K%5BAuthor%5D&cauthor=true&cauthor_uid=3 0431332[/url])¹, Kallem RR ([url]https://www.ncbi.nlm.nih.gov/pubmed/?term=Kallem%20RR%5BAuthor%5D&cauthor=true&cauthor _uid=30431332[/url])², Baker T ([url]https://www.ncbi.nlm.nih.gov/pubmed/?term=Baker%20T%5BAuthor%5D&cauthor=true&cauthor_u id=30431332[/url])³, Hale TW ([url]https://www.ncbi.nlm.nih.gov/pubmed/?term=Hale%20TW%5BAuthor%5D&cauthor=true&cauthor_u id=30431332[/url])¹. Author information ([url]https://www.ncbi.nlm.nih.gov/pubmed/?term=mesalamine+hale+tw#[/url])

Abstract

BACKGROUND:


Oral mesalamine (5-amino salicylic acid [5-ASA]) is an anti-inflammatory agent commonly used to treat inflammatory bowel disease such as ulcerative colitis and Crohn's disease. The transfer of mesalamineinto human milk has to date been poorly described at the current dosages and newer formulations. This study was designed to determine transfer of mesalamine into human milk as a function of maternal dose and time, and dosage form. STUDY DESIGN:


Ten breastfeeding mothers (age 28-41 years) suffering from inflammatory bowel disease were recruited who provided milk samples at 0, 1, 2, 4, 8, 12, and 24 hours after a single daily dose of oral mesalamine in pH-dependent gastroresistant coated tablets (1.2, 2.4, 3.6, and 4.8 g). Milk samples were analyzed using liquid chromatography/tandem mass spectrometry. RESULTS:


A total of 10 women were enrolled for the study. The calibration curve for mesalamine was linear over a concentration range of 0.32-200 ng/mL. Irrespective of maternal dose, mesalamine levels in milk were exceedingly low. However, a wide range of mesalamine levels were observed among all the participants. The relative infant doses were all lower than 0.1% (range 0.003-0.085%). CONCLUSION:


Regardless of dose and high variability, mesalamine levels in human milk were present in exceedingly low levels. The mothers in this study reported no side effects with their infants. These results suggest that the transfer of mesalamine into milk is very low and poses minimal risks to the breastfed infant. KEYWORDS:


5-ASA; human milk; inflammatory bowel disease; mesalamine PMID:30431332